相关实验视频

Updated: Jun 17, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

康格洛尔治疗患者中出血风险上游P2Y₁₂抑制剂治疗:CAMEO注册表

Jennifer Rymer^1,2, Brooke Alhanti², Steven Kemp²

¹Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.

Journal of the Society for Cardiovascular Angiography & Interventions

|August 12, 2024

概括

在患有心肌梗塞 (MI) 的患者中使用康格洛尔 (Cangrelor) 之前暴露于P2Y12抑制剂并没有显著增加出血风险. 这项研究发现,上游口服P2Y12抑制剂使用和不使用的患者之间的出血率相似.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
临床试验临床试验

背景情况:

有限的数据存在于先前用口服P2Y12抑制剂治疗心肌梗塞 (MI) 患者的格勒勒的出血风险.
了解这种风险对于优化抗血小板治疗在急性心脏病发作管理中至关重要.

研究的目的:

为了评估与格罗尔在心肌梗塞 (MI) 患者的治疗相关的出血风险,这些患者先前接受过口服P2Y12抑制剂治疗.
为了比较 cangrelor 治疗的 MI 患者与或没有上游口服 P2Y12 抑制剂暴露之间的出血结果.

主要方法:

康格罗尔在急性心脏病中:有效性和结果 (CAMEO) 登记册前性地收集了康格罗尔治疗心脏病患者的数据.
上游口服P2Y12抑制被定义为在住院治疗前24小时内或在冠状动脉血管造影之前给予.
血液事件在出院后的7天内进行评估,并将具有和没有上游P2Y12抑制剂暴露的组进行比较.

主要成果:

在1802名用康格罗尔治疗的肌痛性心脏病患者中,21.4%的患者有上游口服P2Y12抑制剂的暴露.
在 (6.5%) 和没有 (8.8%) 上游暴露的患者之间没有观察到出血率的统计学上显著差异 (调整后OR,0.62;95% CI,0.38-1.01).
出血率也没有显著差异,这取决于相对于最后一次口服P2Y12抑制剂剂量的格罗尔的时间.

结论:

在先前有或没有口服P2Y12抑制剂暴露的MI患者中,Cangrelor治疗与可比的出血风险有关.
研究结果表明,在这种患者群体中,康格洛尔可以安全地使用,而不会显著增加出血并发症.

关键词:

这是一种P2Y12抑制剂.发生出血,出血.在Cangrelor,我们可以看到Cangrelor.心肌梗塞的心脏病发作

更多相关视频

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.